Outcomes of the 340B Drug Pricing Program
A Scoping Review
Bibliographic Data
| ID | 15808596 |
|---|---|
| Authors | Ryan P Knox (Brigham and Women's Hospital), Junyi Wang (0009-0000-6798-9632, Harvard University), William B Feldman (0000-0003-3467-5869, Brigham and Women's Hospital), Aaron S Kesselheim (0000-0002-8867-2666, Brigham and Women's Hospital), Ameet Sarpatwari (0000-0001-5043-6206, Brigham and Women's Hospital, corresponding author) |
| Year | 2023 |
| Volume | 4 |
| Issue | 11 |
| Pages | e233716-e233716 |
| Publication date | 2023-11-22 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | JAMA Health Forum (JOURNAL) |
| Journal identifiers | ISSN: 2689-0186 • E-ISSN: 2689-0186 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/jamahealthforum.2023.3716 |
| PMID | 37991784 |
| OpenAlex | W4388896152 |
| Language | EN |
| Citations received | 7 |
| References cited | 28 |
In this scoping review of the 340B program, we found that the 340B program was associated with financial benefits for hospitals, clinics, and pharmacies; improved access to health care services for patients; and substantial costs to manufacturers. Increased transparency regarding the use of 340B program revenue and strengthened rulemaking and enforcement authority for the Health Resources and Services Administration would support compliance and help ensure the 340B program achieves its intended purposes
Actuarial science · Agency (philosophy · Audit · Business · Drug pricing · EconLit · Government (linguistics · Health care · Human services · Inspector general · Legislature · MEDLINE · Political science · Revenue · Health Systems, Economic Evaluations, Quality of Life · Healthcare Policy and Management · Law · Medicine · Pharmaceutical industry and healthcare · Accounting
Study Designs and Methods for Health Policy and Health Services Research
Minnesota Law Brings Transparency to the 340B Drug Pricing Program
Implementing Maximum Fair Price Without Hurting Pharmacies
The Association of the 340B Program with Affordable Care Act (ACA) Premiums
Mapping 340B Funds Flow Through Contract Pharmacies
The Association of 340B Program Drug Margins with Covered Entity Characteristics
In Search of Pharmaceutical Policy Innovation in the US
A scoping review on the conduct and reporting of scoping reviews
Understanding scoping reviews
Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States
Scoping studies
Pricing in the Market for Anticancer Drugs
| Unique citing works | 7 |
|---|---|
| Citations per year | 3,5 |
| Citation span | 2024 - 2026 (3) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 7 |